Tanvex BioPharma, Inc. (TPE:6541)
63.30
-0.30 (-0.47%)
Apr 2, 2025, 1:30 PM CST
Tanvex BioPharma Revenue
In the year 2024, Tanvex BioPharma had annual revenue of 34.68M TWD, down -43.53%. Tanvex BioPharma had revenue of 2.81M in the quarter ending December 31, 2024, a decrease of -69.08%.
Revenue
34.68M
Revenue Growth
-43.53%
P/S Ratio
283.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
15.08B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 34.68M | -26.73M | -43.53% |
Dec 31, 2023 | 61.41M | 39.01M | 174.11% |
Dec 31, 2022 | 22.40M | 17.00M | 314.43% |
Dec 31, 2021 | 5.41M | 5.11M | 1,702.00% |
Dec 31, 2020 | 300.00K | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PharmaEssentia | 9.73B |
Caliway Biopharmaceuticals | 44.43M |
Bora Pharmaceuticals Co., LTD. | 19.25B |
Lotus Pharmaceutical | 18.58B |
Oneness Biotech | 117.93M |
Lumosa Therapeutics | 39.15M |
Pegavision | 6.82B |
Polaris Group | 107.00M |